← Back to Home

Kidney Cancer Invading a Major Vein: Preoperative Targeted Radiation Trial Shows a Signal of Recurrence Control

A phase 2 trial involving 23 patients tested radiation to tumors inside a vein before surgical removal. One-year recurrence-free survival met the prespecified study threshold, but whether the approach improves outcomes over standard surgery still requires confirmation in randomized trials.

By SURL BioNews

When kidney cancer grows along blood vessels into the inferior vena cava, treatment challenges extend beyond the kidney itself. Physicians must remove the affected kidney and address the tumor inside a major blood vessel, while patients also face a risk of postoperative recurrence. A small U.S. clinical trial tested the addition of targeted radiation therapy before surgery, offering preliminary clues to addressing this challenge.

The inferior vena cava carries blood from the lower body back to the heart. A “tumor thrombus” formed by kidney cancer is cancer tissue growing into a blood vessel, potentially obstructing blood flow or even extending close to the heart. According to UT Southwestern Medical Center, surgical removal is particularly complex when the tumor thrombus extends above the level of the liver or adheres to the vessel wall, requiring a team with relevant experience.

In the phase 2 study led by the center’s team and published October 15 in *JAMA Oncology*, 23 patients received stereotactic ablative radiotherapy (SABR). This technique concentrates high doses of radiation on specific lesions; the trial targeted the tumor thrombus inside the vein, delivering treatment in three or five sessions. Subsequently, 22 patients underwent removal of the kidney and tumor thrombus within 4 to 14 days, while 21 patients were included in the primary recurrence-free survival analysis.

The study estimated one-year recurrence-free survival at 71.4%, exceeding the prespecified comparison threshold of 55.7% derived from historical data on surgery alone. However, the 95% confidence interval for the 71.4% estimate ranged from 47.2% to 86.0%, indicating substantial uncertainty associated with the small sample. This measure also cannot be interpreted as a cure rate.

The safety findings likewise require a nuanced reading. There were no deaths within 90 days after surgery, and no grade 4 or 5 toxicities attributed to radiation therapy were recorded. However, grade 3 radiation-related adverse events and other serious treatment-related events did occur. The journal summary released by the American Medical Association characterized the findings as showing preliminary feasibility and acceptable safety; this does not mean the overall treatment carries no major risks.

The most important limitation is the absence of a randomized, concurrent surgery control group. Differences in patient characteristics, surgical care, and treatment era could all affect historical comparisons. Meeting the prespecified screening threshold for a phase 2 trial supports further research, but is not yet sufficient to demonstrate that adding radiation therapy is superior to surgery alone. Recurrence or progression during follow-up also predominantly involved distant lesions.

The study also observed that, among three patients who had metastases at enrollment, two experienced shrinkage of unirradiated metastatic lesions without receiving systemic drug therapy. The center suggested that this might involve an “abscopal effect” following local radiation therapy, in which tumors elsewhere in the body also respond. However, changes in a small number of cases cannot establish an immune mechanism, much less predict which patients will benefit.

The next step will test whether this strategy can truly reduce the treatment burden. The center said the team is proposing a national randomized trial to further test whether controlling the tumor thrombus with radiation therapy and surgically removing the affected kidney could reduce the need for major blood vessel surgery. This is a new direction that remains to be validated; patients in the current trial still underwent removal of the tumor thrombus.

References

  1. UT Southwestern Medical Center
  2. American Medical Association / JAMA Network